III期-话题@MedSci

#III期#

681篇内容 | 1796人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594987, encodeId=31ec159498e61, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NANOBIOTIX与联拓生物宣布，用于评估NBTXR3治疗头颈癌的NANORAY-312 III期试验在亚洲完成首位患者招募, objectType=article, longId=738601, objectId=0e2de3860180, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e2de3860180, replyNumber=0, likeNumber=51, createdTime=2022-09-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e2de3860180, moduleTitle=NANOBIOTIX与联拓生物宣布，用于评估NBTXR3治疗头颈癌的NANORAY-312 III期试验在亚洲完成首位患者招募, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e2de3860180)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594986, encodeId=e7d91594986f3, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=联拓生物完成Mavacamten用于治疗中国梗阻性肥厚型心肌病患者的EXPLORER-CN III期关键临床试验的患者招募, objectType=article, longId=735587, objectId=f431e3558751, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f431e3558751, replyNumber=0, likeNumber=32, createdTime=2022-08-12, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f431e3558751, moduleTitle=联拓生物完成Mavacamten用于治疗中国梗阻性肥厚型心肌病患者的EXPLORER-CN III期关键临床试验的患者招募, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f431e3558751)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594985, encodeId=168b1594985c4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=一线治疗晚期肝癌哪家强？《柳叶刀肿瘤学》发布卡博替尼+阿替利珠单抗 vs 索拉非尼III期临床结果, objectType=article, longId=731375, objectId=9d30e31375a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d30e31375a9, replyNumber=0, likeNumber=45, createdTime=2022-07-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d30e31375a9, moduleTitle=一线治疗晚期肝癌哪家强？《柳叶刀肿瘤学》发布卡博替尼+阿替利珠单抗 vs 索拉非尼III期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d30e31375a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594984, encodeId=5473159498491, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=J Clin Oncol：卡培他滨加用奥沙利铂可作为II-III期结直肠癌的替代辅助治疗, objectType=article, longId=731074, objectId=f8d8e3107483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8d8e3107483, replyNumber=0, likeNumber=1, createdTime=2022-07-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8d8e3107483, moduleTitle=J Clin Oncol：卡培他滨加用奥沙利铂可作为II-III期结直肠癌的替代辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8d8e3107483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594983, encodeId=2d05159498340, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！, objectType=article, longId=727998, objectId=c0e7e2799863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0e7e2799863, replyNumber=0, likeNumber=49, createdTime=2022-05-29, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0e7e2799863, moduleTitle=JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0e7e2799863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594981, encodeId=cd6f159498162, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD, objectType=article, longId=727795, objectId=19a7e27795a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19a7e27795a3, replyNumber=0, likeNumber=36, createdTime=2022-05-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19a7e27795a3, moduleTitle=J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19a7e27795a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594982, encodeId=dfc0159498228, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, objectType=article, longId=727788, objectId=2cfae27788c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cfae27788c8, replyNumber=0, likeNumber=40, createdTime=2022-05-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cfae27788c8, moduleTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cfae27788c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594979, encodeId=bd0c15949e997, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, objectType=article, longId=727507, objectId=8299e27507ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8299e27507ba, replyNumber=0, likeNumber=38, createdTime=2022-05-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8299e27507ba, moduleTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8299e27507ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594980, encodeId=bccb15949808f, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性, objectType=article, longId=727505, objectId=e820e275056e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e820e275056e, replyNumber=0, likeNumber=42, createdTime=2022-05-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e820e275056e, moduleTitle=JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e820e275056e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594978, encodeId=822515949e8b2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=GEMSTONE-301，舒格利单抗能否再次撼动不可切除III期肺癌治疗格局？, objectType=article, longId=727255, objectId=541de2725547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=541de2725547, replyNumber=0, likeNumber=39, createdTime=2022-05-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=541de2725547, moduleTitle=GEMSTONE-301，舒格利单抗能否再次撼动不可切除III期肺癌治疗格局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=541de2725547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594977, encodeId=6ca515949e786, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Nat Med：两项多格列艾汀的III期研究结果公布，降糖作用显著且长期持续, objectType=article, longId=726861, objectId=e4bce268618c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4bce268618c, replyNumber=0, likeNumber=43, createdTime=2022-05-15, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4bce268618c, moduleTitle=Nat Med：两项多格列艾汀的III期研究结果公布，降糖作用显著且长期持续, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4bce268618c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594975, encodeId=ed0115949e533, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=绿谷制药GV-971治疗阿尔茨海默病国际多中心III期临床停止, objectType=article, longId=726700, objectId=96ace26700f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96ace26700f7, replyNumber=0, likeNumber=65, createdTime=2022-05-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96ace26700f7, moduleTitle=绿谷制药GV-971治疗阿尔茨海默病国际多中心III期临床停止, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96ace26700f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594976, encodeId=39bc15949e63a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Clin Nutrition: 骨骼肌在切除的III期恶性黑色素瘤的患者中具有预后意义, objectType=article, longId=726495, objectId=d831e2649564, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d831e2649564, replyNumber=0, likeNumber=42, createdTime=2022-05-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d831e2649564, moduleTitle=Clin Nutrition: 骨骼肌在切除的III期恶性黑色素瘤的患者中具有预后意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d831e2649564)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594974, encodeId=340015949e408, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=阿斯利康表示Farxiga达到了III期心力衰竭研究的主要终点, objectType=article, longId=726470, objectId=5a4ce2647008, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a4ce2647008, replyNumber=0, likeNumber=51, createdTime=2022-05-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a4ce2647008, moduleTitle=阿斯利康表示Farxiga达到了III期心力衰竭研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a4ce2647008)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594973, encodeId=a2ce15949e315, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果, objectType=article, longId=726365, objectId=c0f8e2636523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0f8e2636523, replyNumber=0, likeNumber=28, createdTime=2022-05-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0f8e2636523, moduleTitle=长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0f8e2636523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594972, encodeId=c9ca15949e2a7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=辉瑞新冠口服药Paxlovid用于暴露后预防的II/III期临床失败, objectType=article, longId=725951, objectId=a6bfe25951ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6bfe25951ed, replyNumber=0, likeNumber=46, createdTime=2022-05-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6bfe25951ed, moduleTitle=辉瑞新冠口服药Paxlovid用于暴露后预防的II/III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6bfe25951ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594970, encodeId=c5b315949e0b5, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存, objectType=article, longId=723595, objectId=19f4e2359542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19f4e2359542, replyNumber=0, likeNumber=42, createdTime=2022-04-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19f4e2359542, moduleTitle=BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19f4e2359542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594969, encodeId=19641594969ab, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, objectType=article, longId=302280, objectId=14b430228084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14b430228084, replyNumber=0, likeNumber=26, createdTime=2022-04-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b430228084, moduleTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14b430228084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594968, encodeId=7f9b15949683b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=度伐利尤单抗治疗局部晚期宫颈癌III期研究，结果失败, objectType=article, longId=302279, objectId=6eee3022e979, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6eee3022e979, replyNumber=0, likeNumber=47, createdTime=2022-04-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6eee3022e979, moduleTitle=度伐利尤单抗治疗局部晚期宫颈癌III期研究，结果失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6eee3022e979)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594967, encodeId=3d5e159496e83, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）, objectType=article, longId=302278, objectId=941a3022e85a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=941a3022e85a, replyNumber=0, likeNumber=54, createdTime=2022-04-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=941a3022e85a, moduleTitle=NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=941a3022e85a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NANOBIOTIX与联拓生物宣布，用于评估NBTXR3治疗头颈癌的NANORAY-312 III期试验在亚洲完成首位患者招募

2022-09-10

智智灵药 (审核中...)

前往app查看评论内容

#III期#

联拓生物完成Mavacamten用于治疗中国梗阻性肥厚型心肌病患者的EXPLORER-CN III期关键临床试验的患者招募

2022-08-12

智智灵药 (审核中...)

前往app查看评论内容

#III期#

一线治疗晚期肝癌哪家强？《柳叶刀肿瘤学》发布卡博替尼+阿替利珠单抗 vs 索拉非尼III期临床结果

2022-07-07

智智灵药 (审核中...)

前往app查看评论内容

#III期#

J Clin Oncol：卡培他滨加用奥沙利铂可作为II-III期结直肠癌的替代辅助治疗

2022-07-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！

2022-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

J Clin Oncol：选择性雌激素受体降解剂（Elacestrant）对比标准内分泌治疗ER+/HR-晚期乳腺癌的疗效：III期临床研究EMERALD

2022-05-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS

2022-05-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究

2022-05-23

智智灵药 (审核中...)

前往app查看评论内容

#III期#

JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性

2022-05-23

智智灵药 (审核中...)

前往app查看评论内容

#III期#

GEMSTONE-301，舒格利单抗能否再次撼动不可切除III期肺癌治疗格局？

2022-05-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Nat Med：两项多格列艾汀的III期研究结果公布，降糖作用显著且长期持续

2022-05-15

智智灵药 (审核中...)

前往app查看评论内容

#III期#

绿谷制药GV-971治疗阿尔茨海默病国际多中心III期临床停止

2022-05-13

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Clin Nutrition: 骨骼肌在切除的III期恶性黑色素瘤的患者中具有预后意义

2022-05-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

阿斯利康表示Farxiga达到了III期心力衰竭研究的主要终点

2022-05-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果

2022-05-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

辉瑞新冠口服药Paxlovid用于暴露后预防的II/III期临床失败

2022-05-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存

2022-04-07

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究

2022-04-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

度伐利尤单抗治疗局部晚期宫颈癌III期研究，结果失败

2022-04-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NKTR-214联合Opdivo治疗黑色素瘤的两项III期研究，结果失败（PIVOT IO-001）

2022-04-04

科室
- - 订阅+
  - 更多科室
工具
服务